

Abstract Number: CP-163

ONCO-HEMATOLOGICAL OUTPATIENTS TREATED WITH ORAL ANTINEOPLASTIC AGENTS: PHARMACIST INTERVENTIONS

V. Escudero-Vilaplana, R. Collado-Borrell, Á. Giménez-Manzorro, C. Ortega-Navarro, E. Chamorro de Vega, C. Ruiz-Martínez, C. Rodríguez-González, A. Herranz-Alonso, M. Sanjurjo-Sáez

Pharmacy Department, Hospital General Universitario Gregorio Marañón, Spain.

OBJECTIVES

Currently, **oral antineoplastic agents (OAA)** represent around 40% of all chemotherapy. Thus, **onco-hematological outpatients** have acquired more autonomy and responsibility since OAA require self-administration at home. **Hospital pharmacists** are the latest health professionals in touch with patients and should **detect problems related to these drugs (DRP)**.



The **objective** of this study is to assess pharmacist interventions performed in outpatients treated with OAA in a tertiary hospital.

METHODS

- ✓ All **patients who started treatment with OAA** between January and September 2016 in the Outpatient Pharmacy were included.
- ✓ Pharmacist interventions took place during the **pharmacist interview** at the beginning of the treatment.
- ✓ Other **variables** were: demographics, ECOG, type of tumor, OAA and concurrent medication. Severity of DRP was classified as: minor, moderate and serious.
- ✓ These data were **collected** from medical records and also directly from patients in the pharmacist interview.

RESULTS

- **170 patients** (mean age= 67.3 years old, 64.7% male, 7.9% with ECOG \geq 1) were included.
- The most **prevalent tumors**: Prostate cancer (18.8%), renal cancer (17.0%), liver cancer (12.4%) and multiple myeloma (11.2%).
- The most **prevalent OAA**: Sorafenib (11.8%), everolimus (10.6%), abiraterone (10.0%) and lenalidomide (9.4%).
- **84 pharmacist interventions** were performed in **62 different patients** (90.5% in oncological and 9.5% in hematological patients).



OAA ASSOCIATED TO MORE DRUG RELATED PROBLEMS

OAA	DRP/patient
Pazopanib	1.1
Sunitinib	1.0
Enzalutamide	0.8
Erlotinib	0.8
Gefitinib	0.5
Everolimus	0.4
Axitinib	0.4

CONCLUSIONS

- ✓ Pharmacist interventions and follow-up have achieved to detect DRP and improve the treatment of onco-hematological outpatients.
- ✓ The most frequent interventions consisted on identifying drugs and herbs interactions and improving management of side effects.

